- Home
- NTRB vs PMVP Comparison
NTRB vs PMVP Comparison
Compare NTRB & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | PMVP |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7M | 68.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NTRB | PMVP |
|---|---|---|
| Price | $5.05 | $1.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $13.00 | $5.00 |
| AVG Volume (30 Days) | 23.4K | ★ 261.8K |
| Earning Date | 12-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,278,321.00 | N/A |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $3.72 | $0.81 |
| 52 Week High | $11.78 | $1.84 |
Technical Indicators
Market Signals| Indicator | NTRB | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 41.31 | 42.65 |
| Support Level | $4.60 | $1.14 |
| Resistance Level | $5.45 | $1.30 |
| Average True Range (ATR) | 0.36 | 0.06 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 49.84 | 43.48 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.